AKT1 and metabolic syndrome: In later phases of DIO/MetS/T2DM, hepatic IRS‐1 activity and levels diminish, thus causing decreases in IRS‐1/PI3K and Akt activation, and decreases in phosphorylation of other Akt substrates, for example, glycogen synthase kinase‐3β (GSK3β).